Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching antiviral therapy after hepatectomy in HBV-related hepatocellular carcinoma
ChiCTR2200057867Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hepatocellular carcinoma (HCC) and hepatitis B (HBV) comparing Switch to TDF with Continue ETV (2 arms). Primary endpoint: recurrence-free survival. Planned start May 2022; status: not yet recruiting.
02
Drugs
tenofovir disoproxil fumarateentecavir
03
Conditions
hepatocellular carcinoma (HCC)hepatitis B (HBV)
Beyond the preview
Go deeper on ChiCTR2200057867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057867.